Company intelligence / Profile preview

Unibioscreen

Ownership: Private
Employees: ~28
Development stage: Other

Overview

Unibioscreen advanced two novel small molecule oncology compounds (UNBS1450 and UNBS5162) into clinical trials. UNBS5162 reached Phase 1 for cancer with some unique anti-angiogenic and anti-chemokine activity, especially investigated in refractory prostate cancer. No recent data suggest further clinical developments since late 2000s.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Drug pipeline

1 asset

UNBS1450

Unknown

Partnerships

Drais Pharmaceuticals

Beyond the preview

Go deeper on Unibioscreen.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Unibioscreen.